Status:
COMPLETED
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Enterobacteriaceae Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has bec...
Detailed Description
The rising antimicrobial resistance has led to more than 33,000 deaths in Europe in 2015. Among them, extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are the most frequent in Eu...
Eligibility Criteria
Inclusion
- Patient above 18 year-old admitted to intensive care unit
- ESBL-E fecal carriage according to current screening recommendations
- Suspicion of ventilator-associated pneumonia according to ICU society guidelines
Exclusion
- Septic shock according to Sepsis-3 classification
- Neutropenia (neutrophils count \< 500/mm3)
- Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months.
- Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months
- Treatment with piperacillin-tazobactam in the 10 previous days
- Proven hypersensitivity to penicillin or tazobactam
- Pregnancy or breastfeeding
- Curatorship or guardianship
- Prisoners
- No health insurance
Key Trial Info
Start Date :
February 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 22 2024
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04276480
Start Date
February 16 2022
End Date
April 22 2024
Last Update
August 28 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de la Côte Basque
Bayonne, France, 64100
2
Hopital Pellegrin
Bordeaux, France, 33000